Lp-PLA2 levels tended to be higher in individuals who were APOE ε4 carriers in each diagnosis group (Table 4) In the AD diagnosis group, mean Lp-PLA2 activity was 26.2 nmol/min/l higher in individuals with APOE ε4 positive status compared to APOE ε4 negative individuals (P = 0.003). This evidence concerns the gene PLA2G7 and Alzheimer disease.